within Pharmacolibrary.Drugs.ATC.A;

model A02AA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.04,
    Cl             = 0.08333333333333333,
    adminDuration  = 600,
    adminMass      = 1.2,
    adminCount     = 1,
    Vd             = 0.00025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Magnesium hydroxide is an inorganic compound commonly used as an antacid to relieve indigestion, heartburn, and upset stomach, or as a saline laxative for short-term treatment of constipation. It acts by neutralizing stomach acid or by attracting water into the intestines. The drug is widely approved and available OTC in many countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for oral administration in healthy adults; few data published due to very poor absorption from the gastrointestinal tract.</p><h4>References</h4><ol><li><p>Dolberg, MK, et al., &amp; Dahl, R (2017). Pharmacokinetic Profile of Oral Magnesium Hydroxide. <i>Basic &amp; clinical pharmacology &amp; toxicology</i> 120(3) 264–269. DOI:<a href=&quot;https://doi.org/10.1111/bcpt.12642&quot;>10.1111/bcpt.12642</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27412366/&quot;>https://pubmed.ncbi.nlm.nih.gov/27412366</a></p></li><li><p>Patel, G, et al., &amp; Talley, AK (2023). Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects. <i>Antimicrobial agents and chemotherapy</i> 67(4) e0149522–None. DOI:<a href=&quot;https://doi.org/10.1128/aac.01495-22&quot;>10.1128/aac.01495-22</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36943038/&quot;>https://pubmed.ncbi.nlm.nih.gov/36943038</a></p></li><li><p>Scott, G, et al., &amp; Rordorf, C (2004). Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. <i>Clinical pharmacokinetics</i> 43(5) 341–348. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200443050-00006&quot;>10.2165/00003088-200443050-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15080766/&quot;>https://pubmed.ncbi.nlm.nih.gov/15080766</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A02AA04;
